|22.61||+0.0500||+0.22%||Vol 112.06K||1Y Perf -32.07%|
|Nov 25th, 2022 13:00 DELAYED|
|- -||- -%|
|Target Price||54.10||Analyst Rating||Moderate Buy 1.72|
|Potential %||139.28||Finscreener Ranking||★★★★+ 55.92|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★+ 58.77|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 73.40|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||22.20||Earnings Rating||Neutral|
|Market Cap||978.85M||Earnings Date||3rd Nov 2022|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-1.55|
|EPS Growth Next 5 Years %||11.80|
|Avg. Weekly Volume||179.05K|
|Avg. Monthly Volume||293.62K|
|Avg. Quarterly Volume||333.33K|
REGENXBIO Inc. (NASDAQ: RGNX) stock closed at 22.61 per share at the end of the most recent trading day (a 0.22% change compared to the prior day closing price) with a volume of 112.06K shares and market capitalization of 978.85M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 257 people. REGENXBIO Inc. CEO is Kenneth T. Mills.
The one-year performance of REGENXBIO Inc. stock is -32.07%, while year-to-date (YTD) performance is -30.86%. RGNX stock has a five-year performance of -23.74%. Its 52-week range is between 18.69 and 36.35, which gives RGNX stock a 52-week price range ratio of 22.20%
REGENXBIO Inc. currently has a PE ratio of 12.60, a price-to-book (PB) ratio of 1.67, a price-to-sale (PS) ratio of 1.95, a price to cashflow ratio of 5.60, a PEG ratio of 2.32, a ROA of 9.43%, a ROC of 15.84% and a ROE of 15.43%. The company’s profit margin is 10.39%, its EBITDA margin is 25.80%, and its revenue ttm is $480.03 Million , which makes it $11.09 revenue per share.
Of the last four earnings reports from REGENXBIO Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-1.55 for the next earnings report. REGENXBIO Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for REGENXBIO Inc. is Moderate Buy (1.72), with a target price of $54.1, which is +139.28% compared to the current price. The earnings rating for REGENXBIO Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
REGENXBIO Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
REGENXBIO Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 10.77, ATR14 : 1.19, CCI20 : 42.34, Chaikin Money Flow : -0.05, MACD : -0.30, Money Flow Index : 59.03, ROC : 8.65, RSI : 52.23, STOCH (14,3) : 71.26, STOCH RSI : 1.00, UO : 52.95, Williams %R : -28.74), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of REGENXBIO Inc. in the last 12-months were: Allan M. Fox (Sold 112 869 shares of value $3 915 359 ), Steve Pakola (Sold 1 598 shares of value $53 933 ), Vittal Vasista (Option Excercise at a value of $25 415), Vittal Vasista (Sold 27 280 shares of value $913 648 )
Thu, 04 Aug 2022 17:25 GMT Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX) and Autolus Therapeutics (AUTL)- TipRanks. All rights reserved.
Thu, 04 Aug 2022 13:13 GMT RegenXBio (RGNX) Receives a Buy from Berenberg Bank- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.